Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions

Anna W. Chalmers, Jamile M. Shammo*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Abstract

Transfusion-dependent anemia is a common feature in a wide array of hematological disorders, including thalassemia, sickle cell disease, aplastic anemia, myelofibrosis, and myelodysplastic syndromes. In the absence of a physiological mechanism to excrete excess iron, chronic transfusions ultimately cause iron overload. Without correction, iron overload can lead to end-organ damage, resulting in cardiac, hepatic, and endocrine dysfunction/failure. Iron chelating agents are utilized to reduce iron overload, as they form a complex with iron, leading to its clearance. Iron chelation has been proven to decrease organ dysfunction and improve survival in certain transfusion-dependent anemias, such as β-thalassemia. Several chelating agents have been approved by the United States Food and Drug Administration for the treatment of iron overload, including deferoxamine, deferiprone, and deferasirox. A variety of factors have to be considered when choosing an iron chelator, including dosing schedule, route of administration, tolerability, and side effect profile. Deferasirox is an orally administered iron chelator with proven efficacy and safety in multiple hematological disorders. There are two formulations of deferasirox, a tablet for suspension, and a new tablet form. This paper is intended to provide an overview of iron overload, with a focus on deferasirox, and its recently approved formulation Jadenu® for the reduction of transfusional iron overload in hematological disorders.

Original languageEnglish (US)
Pages (from-to)201-208
Number of pages8
JournalTherapeutics and Clinical Risk Management
Volume12
DOIs
StatePublished - Feb 15 2016

Keywords

  • Deferasirox
  • Iron chelation therapy
  • Transfusional iron overload

ASJC Scopus subject areas

  • General Pharmacology, Toxicology and Pharmaceutics
  • Pharmacology (medical)
  • Chemical Health and Safety
  • Safety Research

Fingerprint

Dive into the research topics of 'Evaluation of a new tablet formulation of deferasirox to reduce chronic iron overload after long-term blood transfusions'. Together they form a unique fingerprint.

Cite this